Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-center open-label phase IIa study of Omecaxone sodium for reversal of deep rocuronium-induced neuromuscular blockade during elective surgery
CTR20191479Phase 2Completed
- Sponsor
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omecaxone sodium in neuromuscular block (NMB), sponsored by Zhejiang Xianju Pharmaceutical Co., Ltd.. Started Jul 2019; status: completed.
02
Drugs
omecaxone sodium
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20191479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191479.